Methods of Treating Pulmonary Sarcoidosis With DNA Nucleases
Summary
USPTO published patent application US20260109959A1 on April 23, 2026, disclosing methods for treating pulmonary sarcoidosis via inhalation of human recombinant DNase1 or other DNA nucleases. The application, filed January 18, 2025, names inventors Brian William Davies, Daniel S. Cartwright, and Ira Kalfus. The invention proposes that DNA nucleases reduce excessive lung DNA that stimulates TLR9 receptors, thereby decreasing inflammation, cytokine release, and granuloma formation characteristic of sarcoidosis.
“The present invention is directed at methods for treating pulmonary sarcoidosis comprising the therapeutic administration of human recombinant DNase1 or other DNA nuclease enzymes directly inhaled into the lungs.”
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 264 changes logged to date.
What changed
USPTO published patent application US20260109959A1 disclosing therapeutic methods for pulmonary sarcoidosis involving direct inhalation of DNA nuclease enzymes, specifically human recombinant DNase1. The application describes a mechanism where DNA nucleases break down excessive microbial, mitochondrial, and free DNA in the lungs that would otherwise activate TLR9 receptors and trigger inflammatory cytokine cascades leading to fibrosis and granuloma formation.
Pharmaceutical and biotechnology companies developing respiratory or inflammatory therapies may find this application relevant for freedom-to-operate analysis or potential licensing discussions. Researchers in pulmonary medicine and immunology should monitor the prosecution history for scope limitations that may affect future therapeutic applications of DNA nuclease technology for granulomatous diseases.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS OF TREATING PULMONARY SARCOIDOSIS WITH DNA NUCLEASES
Application US20260109959A1 Kind: A1 Apr 23, 2026
Inventors
Brian William Davies, Daniel S. Cartwright, Ira Kalfus
Abstract
The present invention is directed at methods for treating pulmonary sarcoidosis comprising the therapeutic administration of human recombinant DNase1 or other DNA nuclease enzymes directly inhaled into the lungs. DNA nucleases are used herein for the breakdown of excessive lung microbial, mitochondrial, and other free DNA. Such excessive DNA enters dendritic cells and macrophages by way of toll receptor 2 (TLR2) to stimulate toll receptor 9 (TLR9). The TLR9 receptor initiates the inflammation cascade in sarcoidosis with release of pro-inflammatory cytokines and resultant inflammatory cascade resulting in fibrosis and granuloma formations. Therapeutically dosed DNA nucleases such as recombinant human DNase 1 inhaled into sarcoidosis lungs reduce excessive DNA levels, and the associated stimulation of cytokines, inflammation, and granulomas. DNase 1 therapy would reduce inflammation and treat the cause of the pulmonary sarcoidosis. DNase 1 would be used to reduce the dose of steroid therapies and their concomitant serious complications.
CPC Classifications
C12N 9/22 A61K 9/0073 A61P 11/00 A61P 37/06 A61K 38/00 C12Y 301/21001
Filing Date
2025-01-18
Application No.
19031963
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.